6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04706065 (ClinicalTrials.gov)	January 31, 2021	3/1/2021	SHMT1 Polymorphism in Parkinson's Disease,	Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease	Study the Role of SHMT1 Polymorphism in Parkinson Disease	Genetic: SHMT1 polymorphism	Assiut University	Aswan University Hospital	Recruiting	50 Years	N/A	All	80		Egypt
2	NCT02579473 (ClinicalTrials.gov)	January 2016	13/10/2015	A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214	A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration	Parkinson's Disease	Drug: SER-214	Serina Therapeutics	NULL	Active, not recruiting	40 Years	80 Years	All	20	Phase 1	United States
3	NCT00215904 (ClinicalTrials.gov)	August 2003	18/9/2005	D-serine Adjuvant Treatment for Parkinson's Disease	D-serine Adjuvant Treatment for Parkinson's Disease	Parkinson's Disease	Drug: D-serine (~2g/day)	Herzog Hospital	NULL	Completed	30 Years	75 Years	Both	13	Phase 4	Israel